ArticleFrontiers in cardiovascular medicine2025
Elucidating the preventive and therapeutic effects of cardiac telocytes paracrine microRNAs on ischemic heart disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Telocytes Twenty Years on: A Critical Reappraisal of Identity, Function, and Pathological Relevance.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telocytes (TCs), a newly identified type of mesenchymal cell since 2010, possess substantial potential in maintaining tissue homeostasis, orchestrating organ development, and facilitating tissue regeneration. Their distribution in blood, the adventitia of blood vessels, and the intima implies a close association with vascular function. Ischemic heart disease (IHD), a significant challenge in cardiovascular disease, is characterized by the occlusion of major vessels, obstruction of collateral circulation, and disruption of the capillary network-pathological features closely linked to endothelial cell damage. Myocardial tissue is rich in cardiac telocytes (cTCs), which, following myocardial injury, can secrete numerous miRNAs that promote angiogenesis, including miR-let-7e, miR-10a, and miR-126-3p. This indicates that cTCs may have therapeutic potential for IHD. The primary mechanism by which cTCs-derived exosomes exert paracrine effects is through reducing endothelial cell injury, suggesting that enhancing the production of cTCs could offer a novel therapeutic approach for treating IHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.